Case Report
Tuberculosis and Melioidosis at Distinct Sites Occurring Simultaneously
Table 1
Summary of pertinent laboratory investigation results and medications used for treatment of tuberculosis and melioidosis.
| | Baseline results | Initiation of tuberculosis treatment | 2 weeks into tuberculosis treatment | Initiation of treatment of melioidosis | 6 weeks into treatment of melioidosis |
| | ALT 90 U/L | Rifampicin 600 mg OD | ALT 253 U/L | Rifampicin 600 mg OD | ALT 31 U/L | | AST 46 U/L | Isoniazid isoniazid 300 mg OD | AST 526 U/L | Isoniazid isoniazid 300 mg OD | AST 91 U/L | | Bil 11 μmol/L | Ethambutol 900 mg OD | Bil 90.7 μmol/L | Ethambutol 900 mg OD | Bil 15.7 μmol/L | | ALP 444 U/L | Pyrazinamide 1.5 g OD | ALP 444 U/L | Ceftazidime 2 g Q8H | ALP 56 U/L | | Creat 147 μmol/L | | Creat 99 μmol/L | | Creat 157 μmol/L | | Hb 14.4 g/dl | | Hb 14.2 g/dl | | Hb 10.8 g/dl | | WBC 10.88 × 109/L | | WBC 8.0 × 109/L | | WBC 1.1 × 109/L | | Plt 298 × 109/L | | Plt 206 × 109/L | | Plt 217 × 109/L |
|
|
Hemoglobin (Hb) 13–17 g/dL, white blood cell count (WBC) 4–10 × 103/μL, platelet (Plt) 150–450 × 103/μL, creatinine (Creat) 65–125 μmol/L, alanine transaminase (ALT) 10–55 U/L, aspartate transaminase (AST) 10–45 U/L, bilirubin (Bil) 5.0–30.0 μmol/L, albumin (Alb) 37–51 g/dL, alkaline phosphatase (ALP) 32–103 U/L, and once daily (OD).
|
